Abstract
This article provides an example of a smooth and successful withdrawal of long-term and unjustified use of a diuretic (torasemide) in patients with type 2 diabetes mellitus with comorbid obesity by prescribing sodium-glucose cotransporter type 2 inhibitor (dapagliflozin).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have